Evidence map›Paper›PMID 40805215›Full record

ArticleCancers2025

The HIV Protease Inhibitor Ritonavir Reverts the Mesenchymal Phenotype Induced by Inflammatory Cytokines in Normal and Tumor Oral Keratinocytes to an Epithelial One, Increasing the Radiosensitivity of Tumor Oral Keratinocytes.

Silvia Pomella, Lucrezia D'Archivio, Matteo Cassandri, Francesca Antonella Aiello, Ombretta Melaiu, Francesco Marampon, Rossella Rota, Giovanni Barillari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvia PomellaDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7007-4238
Lucrezia D'ArchivioDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.ORCID 0000-0002-3202-2349
Matteo CassandriDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.ORCID 0000-0002-2919-676X
Francesca Antonella AielloDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.ORCID 0000-0003-3013-4504
Ombretta MelaiuDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7118-5186
Francesco MaramponDepartment of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-0588-3039
Rossella RotaDepartment of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.ORCID 0000-0002-9408-7711
Giovanni BarillariDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-3423-4852

Funding

Italian Ministry of University and Research (MUR), University Scientific Research Projects 2021 E83C22002040005
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AKTcell invasioncell survivalEMTinflammationinterleukinsOPMDOSCCradiosensitivityritonavir

Identifiers

PMID40805215
PMCPMC12346649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.